Treatment of Congenital Telangiectasia (Coat's Disease) With Open-label Anecortave Acetate (15mg.)
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
Congenital Telangiectasia or Coat's disease is an uncommon disorder that involves the growth
of blood vessels of the macula. These blood vessels msy extend beneth the retina to produce
an area of sub-retinal neovascularization(growth of abnormal blood vessels under the retina
which "leak" fluid, causing reduction in vision). Limited forms of treatment are available in
managing the neovascularization and its consequences. Anecortave Acetate injection will be
considered as an attempt to control the growth of the abnormal blood vessels.